CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,284 enrolled
Drug / intervention
Rivaroxaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02168829
NCT02168829Phase 4Completed

The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Ottawa Heart Institute Research Corporation·interventional·Posted Jun 20, 2014·Updated Oct 6, 2025

In Brief

A Phase 4 clinical trial evaluating Rivaroxaban and Acetylsalicylic acid for Atrial Fibrillation and Stroke. Completed, enrolled 1,284 participants across 55 sites in 6 countries.

Detailed Summary

This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia. AF is normally associated with an increased risk of stroke which in many patients can be prevented with appropriate blood thinner therapy. This trial will compare a strategy of oral anticoagulant therapy after successful ablation to therapy with an aspirin per day.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Canada, China, Germany, Israel

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 20, 2014
Enrollment StartJan 1, 2016
Primary CompletionAug 14, 2025
TodayJul 2, 2026
Enrollment to primary: 9.6 yearsPosted 12.0 years ago

Interventions

Rivaroxabandrug

Acetylsalicylic aciddrug